Remnant lipoprotein particles and cardiovascular disease risk

Elsevier

Available online 8 June 2022, 101682

Best Practice & Research Clinical Endocrinology & MetabolismAbstract

Intravascular catabolism of chylomicrons and very low-density lipoproteins (VLDLs) gives rise to a spectrum of partially lipolyzed remnant particles. Their plasma levels and properties are influenced by lipases, lipid transfer proteins, and content of exchangeable lipoproteins. Particularly important among the latter are apoE, which mediates hepatic binding and uptake of remnants, and apoCIII, which can retard this process. In the course of their plasma transit, remnants can acquire pathologic properties that promote the development of atherosclerotic cardiovascular disease (ASCVD including increased cholesterol content and transport of thrombogenic and inflammatory mediators. Levels of cholesterol-enriched remnant particles determined by various analytic techniques have been significantly linked to the incidence of ASCVD, most dramatically in dyslipidemic patients homozygous for the apoE2 genetic isoform. Further research is warranted for development of clinical assays that can better capture the pathologic impact of remnant lipoprotein subspecies, and for testing the impact on ASCVD of therapies that reduce their levels.

Keywords

Remnant lipoproteins

chylomicrons

very low density lipoproteins

atherosclerosis

cardiovascular disease

View full text

© 2022 Published by Elsevier Ltd.

留言 (0)

沒有登入
gif